Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma PLC welcomes new investors with fund-raising

Shares were placed at 35p each, a discount of around 4.3% to Tuesday night's close.
Microscope
Redx has a pipeline of potentially best-in-class therapies targeting immuno-oncology and cancer stem cells.

Cancer and autoimmune treatments developer Redx Pharma PLC (LON:REDX) has raised funds from new and existing shareholders to advance its drugs pipeline.

The company raised £10mln by placing 28.6mln shares at 35p a share, 8.5p below last night's closing mid-market price.

Most of the net proceeds of £9.7mln will be used to advance the company's development pipeline, including progressing the Porcupine programme, where Redx is working on an enzyme that is liked with pancreatic and triple negative breast cancer, towards the first in-human clinical trials, expected in the first quarter of next year.

Redx also has a number of other early-stage assets under development in immuno-oncology, infection and immunology.

"We are delighted to have successfully raised these new funds with approximately half coming from new institutional investors and also with very strong support from our existing shareholders,” said Neil Murray, chief executive officer.

“We have made excellent progress in the last 12 months especially with our drug discovery programs, having achieved in-vivo proof of concept in a further three programmes and selecting four drug candidates for progression into development. These new funds will support Redx's continuing progress and our existing pipeline. We believe that the assets in our pipeline look extremely promising and offer the potential to deliver significant shareholder value," Murray said.

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

hepatitisC.jpg
July 27 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe
biotechLatest.jpg
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
picture of doctors
July 11 2017
The focus has switched to new, higher value “finished device products”,

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use